I think in 10 years we will look back at this period of time as the turning point when these new treatments, which will allow doctors and research to learn more about this disease, started to offer real hope for this devastating disease.
Breaking News: The FDA has granted approval of Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. We celebrate Kisunla’s approval as more options mean greater opportunity for more time. This is the third approval of an Alzheimer’s treatment that changes the underlying course of the disease. bit.ly/3XIyyvf